Drug Profile
BIBW 22BS
Alternative Names: BIBW 022; BIBW 22Latest Information Update: 15 Oct 2003
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim Pharma KG
- Class Antineoplastics; Pyrimidines
- Mechanism of Action P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 15 Oct 2003 QC
- 18 May 2001 No-Development-Reported for Cancer in Germany (Unknown route)
- 29 Mar 1997 Preclinical development for Cancer in Germany (Unknown route)